



Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025

October 27, 2025

DUBLIN, Oct. 27, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2025 financial results and provide a business update after market close on Monday, November 10, 2025. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EST (2:00 pm PST / 10:00 pm GMT) that day.

Conference Call Information

To participate in the live call by telephone, please pre-register [here](#). Those interested in the live audio webcast of the conference call may access it by [clicking here](#) or visiting the [Events and Presentation](#) page under the Investors Section on [Theravance Biopharma's website](#).

A replay of the webcast will be available on Theravance Biopharma's website for 30 days through December 10, 2025.

About Theravance Biopharma

Theravance Biopharma, Inc.'s focus is to deliver *Medicines that Make a Difference*[®] in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI[®] (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.

For more information, please visit www.theravance.com.

THERAVANCE BIOPHARMA[®], THERAVANCE[®] and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).

YUPELRI[®] is a registered trademark of Viatris Specialty LLC. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.

Contact:

investor_relations@theravance.com

650-808-4045

 View original content to download multimedia: <https://www.prnewswire.com/news-releases/theravance-biopharma-to-report-third-quarter-2025-financial-results-on-november-10-2025-302594981.html>

SOURCE Theravance Biopharma, Inc.